Nels C Knutson1, Pamela P Samson1, Geoffrey D Hugo1, S Murty Goddu1, Francisco J Reynoso1, James A Kavanaugh1, Sasa Mutic1, Kaitlin Moore2, Jessica Hilliard1, Phillip S Cuculich3, Clifford G Robinson4. 1. Department of Radiation Oncology, Washington University School of Medicine, Saint Louis, Missouri. 2. Division of Cardiology, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri. 3. Department of Radiation Oncology, Washington University School of Medicine, Saint Louis, Missouri; Division of Cardiology, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri. 4. Department of Radiation Oncology, Washington University School of Medicine, Saint Louis, Missouri; Division of Cardiology, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri. Electronic address: clifford.robinson@wustl.edu.
Abstract
PURPOSE: A prospective phase 1/2 trial for electrophysiologic guided noninvasive cardiac radioablation treatment of ventricular tachycardia (ENCORE-VT) demonstrating efficacy for arrhythmia control has recently been reported. The treatment workflow, report dose-volume metrics, and overall process improvements are described here. METHODS AND MATERIALS: Patients receiving 25 Gy in a single fraction to the cardiac ventricular tachycardia substrate (identified on presimulation multimodality imaging) on the phase 1/2 trial were included for analysis. Planning target volume (PTV), R50, monitor unit ratio, and gradient measure values were compared over time using statistical process control. Outlier values in the dose-volume histogram (DVH) for PTV and organs at risk were identified by calculating inner fences based on the interquartile range. Median heart substructure doses are also reported. RESULTS: For the 16 trial patients included, the median target volumes for the gross "target" volumes, internal target volumes, and PTVs were 25.1 cm3 (minimum: 11.5 cm3, maximum: 54.9 cm3), 30.1 cm3 (17.7, 81.6), and 97.9 cm3 (66, 208.5), respectively. On statistical process control analysis, there was a significant decrease in PTV volume among the more recent cohort of cases and mean doses to the nontargeted heart (heart - PTV). Two patients had heart-minus-PTV, esophagus, and stomach DVH data significantly higher than inner fence, and 3 patients had spinal cord DVH data higher than the inner fence, but in all cases the deviations were clinically acceptable. Subjective decreases were seen in the R50, gradient measure, and treatment time from the first to last patient in this series. All plans were verified in phantom with ionization chamber measurements within 2.9% of the expected dose value. CONCLUSIONS: Over the duration of this trial, PTV volumes to the cardiac substrate target decreased significantly, and organ-at-risk constraints were met for all cases. Future directions for this clinical process will include incorporating knowledge-based planning techniques and evaluating the need for substructure optimization.
PURPOSE: A prospective phase 1/2 trial for electrophysiologic guided noninvasive cardiac radioablation treatment of ventricular tachycardia (ENCORE-VT) demonstrating efficacy for arrhythmia control has recently been reported. The treatment workflow, report dose-volume metrics, and overall process improvements are described here. METHODS AND MATERIALS: Patients receiving 25 Gy in a single fraction to the cardiac ventricular tachycardia substrate (identified on presimulation multimodality imaging) on the phase 1/2 trial were included for analysis. Planning target volume (PTV), R50, monitor unit ratio, and gradient measure values were compared over time using statistical process control. Outlier values in the dose-volume histogram (DVH) for PTV and organs at risk were identified by calculating inner fences based on the interquartile range. Median heart substructure doses are also reported. RESULTS: For the 16 trial patients included, the median target volumes for the gross "target" volumes, internal target volumes, and PTVs were 25.1 cm3 (minimum: 11.5 cm3, maximum: 54.9 cm3), 30.1 cm3 (17.7, 81.6), and 97.9 cm3 (66, 208.5), respectively. On statistical process control analysis, there was a significant decrease in PTV volume among the more recent cohort of cases and mean doses to the nontargeted heart (heart - PTV). Two patients had heart-minus-PTV, esophagus, and stomach DVH data significantly higher than inner fence, and 3 patients had spinal cord DVH data higher than the inner fence, but in all cases the deviations were clinically acceptable. Subjective decreases were seen in the R50, gradient measure, and treatment time from the first to last patient in this series. All plans were verified in phantom with ionization chamber measurements within 2.9% of the expected dose value. CONCLUSIONS: Over the duration of this trial, PTV volumes to the cardiac substrate target decreased significantly, and organ-at-risk constraints were met for all cases. Future directions for this clinical process will include incorporating knowledge-based planning techniques and evaluating the need for substructure optimization.
Authors: David Krug; Oliver Blanck; Thomas Demming; Matthias Dottermusch; Karoline Koch; Markus Hirt; Laura Kotzott; Adrian Zaman; Lina Eidinger; Frank-Andre Siebert; Jürgen Dunst; Hendrik Bonnemeier Journal: Strahlenther Onkol Date: 2019-10-31 Impact factor: 3.621
Authors: Justin Lee; Matthew Bates; Ewen Shepherd; Stephen Riley; Michael Henshaw; Peter Metherall; Jim Daniel; Alison Blower; David Scoones; Michele Wilkinson; Neil Richmond; Clifford Robinson; Phillip Cuculich; Geoffrey Hugo; Neil Seller; Ruth McStay; Nicholas Child; Andrew Thornley; Nicholas Kelland; Philip Atherton; Clive Peedell; Matthew Hatton Journal: Open Heart Date: 2021-11
Authors: Cristiano Q M Reis; Brian Little; Robert Lee MacDonald; Alasdair Syme; Christopher G Thomas; James L Robar Journal: J Appl Clin Med Phys Date: 2021-10-22 Impact factor: 2.102
Authors: Lukas Knybel; Jakub Cvek; Radek Neuwirth; Otakar Jiravsky; Jan Hecko; Marek Penhaker; Marek Sramko; Josef Kautzner Journal: Rep Pract Oncol Radiother Date: 2021-02-25
Authors: Zi Ouyang; Paul Schoenhagen; Oussama Wazni; Patrick Tchou; Walid I Saliba; John H Suh; Ping Xia Journal: J Appl Clin Med Phys Date: 2020-09-12 Impact factor: 2.102
Authors: Nicholas Hardcastle; Olivia Cook; Xenia Ray; Alisha Moore; Kevin L Moore; David Pryor; Alana Rossi; Farshad Foroudi; Tomas Kron; Shankar Siva Journal: Radiat Oncol Date: 2021-08-03 Impact factor: 3.481